ESR1 and pituitary gland adenoma: As most of the effects of estrogen are mediated though alpha and beta estrogen receptors, the use of fulvestrant, an ESR1 antagonist used for the treatment of post-menopausal women with hormone-sensitive breast cancer, could inhibit the growth of pituitary adenomas through inducing apoptosis, and may be valuable in some cases [43].